Report Details:
15 Companies Covered
200 Pages
Age-Related Macular Degeneration Market Highlights
The Age-Related Macular Degeneration Market Size was estimated at 8.45 USD Billion in 2024. The Age-Related Macular Degeneration industry is projected to grow from 9.163 USD Billion in 2025 to 20.59 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.43% during the forecast period 2025 - 2035.
The Global Age-Related Macular Degeneration Market refers to the market encompassing the diagnosis, treatment, and management of AMD on a global scale. This market includes various products, services, and technologies used to address AMD, such as medications, medical devices, surgical interventions, and supportive therapies.
Market growth is driven by the increasing awareness about eye health, improved healthcare infrastructure, and the rising demand for effective AMD treatments.
Key Players:
MRFR recognizes the following companies as the key players in the Global Age-Related Macular Degeneration Market— Hoffmann-La Roche AG, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc, ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc., GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., and Bayer AG.
Segment Analysis
The Global Age-Related Macular Degeneration Market has been segmented based on type, stage and administration.
On the basis of type, the market is segmented into wet age-related macular degeneration and dry age-related macular degeneration. The increasing use of VEGF inhibitors, which are generally used to treat wet AMD, is the main factor fueling the expansion of this market segment.
Based on stage, the market has been segmented into Intermediate Stage, Early Stage and Late Stage. In this stage, the retinal pigment epithelium (RPE), which is made up of cells that promote the health of the retina, has undergone changes and there are either numerous medium-sized drusen or at least one giant drusen in one or both eyes.
Based on administration, the market has been segmented into intravitreal and intravenous. The utility segment dominated the age-related macular degeneration market in 2024 and is projected to be the faster-growing segment during the forecast period, 2025 -2035 owing to the fact that the tailored drug delivery makes it more efficient.
Regional Analysis
The Global Age-Related Macular Degeneration Market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Age-Related Macular Degeneration Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe.
The Global Age-Related Macular Degeneration Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Global Age-Related Macular Degeneration Market comprises of Middle East, Africa, and Latin America.
North America is one of the major markets for AMD due to its well-established healthcare infrastructure and a large aging population. Countries like the United States and Canada have a significant prevalence of AMD, driving the demand for diagnosis and treatment options.
European countries also have a substantial AMD market, with a growing elderly population and increasing awareness about eye health. Countries such as the United Kingdom, Germany, France, and Italy are important contributors to the regional market.
The Asia-Pacific region has seen a rise in the prevalence of AMD due to its aging population and changing lifestyle factors. Countries like Japan, China, India, and South Korea are witnessing increased cases of AMD, leading to a growing demand for effective treatments.
Furthermore, the rest of the world's Global Concussions Market is divided into the Middle East, Africa, and Latin America. The AMD market in Latin America is also growing, driven by an aging population and improving access to healthcare services.
Key Findings of the Study
- The emergence of innovative therapies is reshaping treatment paradigms in the Age-Related Macular Degeneration Market.
- North America remains the largest market, while Asia-Pacific is identified as the fastest-growing region for AMD treatments.
- Dry Age-Related Macular Degeneration continues to dominate the market, whereas Wet Age-Related Macular Degeneration is witnessing rapid growth.
- Rising prevalence of Age-Related Macular Degeneration and advancements in treatment modalities are key drivers propelling market expansion.
